Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS

Detalles Bibliográficos
Autores principales: Seyger, M.M.B., Reich, A., El Baou, C., Schuster, C., Riedl, E., Paller, A.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291077/
https://www.ncbi.nlm.nih.gov/pubmed/34320259
http://dx.doi.org/10.1111/jdv.17564
_version_ 1784749058940731392
author Seyger, M.M.B.
Reich, A.
El Baou, C.
Schuster, C.
Riedl, E.
Paller, A.S.
author_facet Seyger, M.M.B.
Reich, A.
El Baou, C.
Schuster, C.
Riedl, E.
Paller, A.S.
author_sort Seyger, M.M.B.
collection PubMed
description
format Online
Article
Text
id pubmed-9291077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92910772022-07-20 Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS Seyger, M.M.B. Reich, A. El Baou, C. Schuster, C. Riedl, E. Paller, A.S. J Eur Acad Dermatol Venereol Letters to the Editor John Wiley and Sons Inc. 2021-08-27 2021-12 /pmc/articles/PMC9291077/ /pubmed/34320259 http://dx.doi.org/10.1111/jdv.17564 Text en © 2021 Eli Lilly. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Seyger, M.M.B.
Reich, A.
El Baou, C.
Schuster, C.
Riedl, E.
Paller, A.S.
Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
title Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
title_full Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
title_fullStr Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
title_full_unstemmed Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
title_short Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
title_sort efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from ixora‐peds
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291077/
https://www.ncbi.nlm.nih.gov/pubmed/34320259
http://dx.doi.org/10.1111/jdv.17564
work_keys_str_mv AT seygermmb efficacyofixekizumabonnailpsoriasisinpaediatricpatientswithmoderatetoseverepsoriasisaposthocanalysisfromixorapeds
AT reicha efficacyofixekizumabonnailpsoriasisinpaediatricpatientswithmoderatetoseverepsoriasisaposthocanalysisfromixorapeds
AT elbaouc efficacyofixekizumabonnailpsoriasisinpaediatricpatientswithmoderatetoseverepsoriasisaposthocanalysisfromixorapeds
AT schusterc efficacyofixekizumabonnailpsoriasisinpaediatricpatientswithmoderatetoseverepsoriasisaposthocanalysisfromixorapeds
AT riedle efficacyofixekizumabonnailpsoriasisinpaediatricpatientswithmoderatetoseverepsoriasisaposthocanalysisfromixorapeds
AT palleras efficacyofixekizumabonnailpsoriasisinpaediatricpatientswithmoderatetoseverepsoriasisaposthocanalysisfromixorapeds

Ejemplares similares